Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), today announced that the Wholesale Acquisition Cost (WAC) for ZTlido (lidocaine topical system) 1.8% (ZTLIDO) is $8.98 per patch and is now listed in pricing compendia.
Scilex expects commercial availability of ZTlido through wholesale distribution in October 2018.
‘We are excited to bring our first commercial product to the market,’ said George Ng, President, Business, of Scilex. ‘With ZTlido, we are proud to offer a non-opioid alternative and option for patients with post-herpetic neuralgia.’
ZTLIDO is a topical product that uses an advanced adhesion technology providing more efficient lidocaine delivery than Lidoderm over a full 12 hours. Post-herpetic neuralgia (PHN), also referred to as post-shingles pain, is a frequent complication of shingles, a condition caused by the herpes zoster (HZ) virus, which afflicts an estimated 1 million people each year in the US.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.